INTRODUCTION

Human Immunodeficiency Virus infection and Acquired Immune Deficiency Syndrome commonly referred to as HIV/AIDS has emerged as being the most serious and challenging public health problems in the world. Since the first case of AIDS occurred in 1981 with a report of Pneumocystis carinii pneumonia and Kaposi’s sarcoma in homosexual men in the United States, AIDS has become a major worldwide epidemic. Today an estimated 30.6 million people are living with HIV infection or AIDS [1].

HIV begins its infection of a susceptible host cell by binding to the CD4 receptor on the host cell. Following fusion of the virus with the host cell, HIV enters the cell. The virus RNA is released and undergoes reverse transcription into DNA by an enzyme in HIV called reverse transcriptase. Once the genetic material of HIV has been changed into DNA, this viral DNA enters the host cell nucleus where it can be integrated into the genetic material of the cell. Once the viral DNA is integrated into the genetic material of the host, it is possible that HIV may persist in a latent state for many years [2-5].

Activation of the host cells results in the transcription of viral DNA into messenger RNA (mRNA), which is then translated into viral proteins. The new viral RNA forms the genetic material of the next generation of viruses. The viral RNA and viral proteins assemble at the cell membrane into a new virus. Following assembly at the cell surface, the virus then buds forth from the cell and is released to infect another cell [6].

AZT is a strong inhibitor of reverse transcriptase and is effective in the treatment of AIDS. Although orally administered AZT is rapidly absorbed from intestinal mucosa it loses considerable potency during its first pass metabolism (40%) and is rapidly eliminated from the body with a half-life of 1 hour. Oral administration of AZT often show strong side effects on bone marrow resulting in leukopenia which may be attributed to an excessive plasma level of AZT immediately after administration [7]. Therefore an adequate Zero order release system is desired to decrease the high daily dose of AZT (5-10 mg/kg every 4 H) to maintain an expected antiviral effect, to reduce the strong side effect and to improve patient compliance [8-10]. The development of a sustained release device and formulation of AZT would be beneficial in comparisons with the recent intermittent dose regimens. Biodegradable sustained release microspheres have been developed for the numerous bioactive reagents. The most significant candidate for biodegradable polymeric controlled release system is the poly (Lactide-Co-Glycolide) due to its controllable biodegradability and good biocompatibility. Synthetic biodegradable polymers have gained more popularity than natural biodegradable polymers. The major advantages of synthetic polymers include high purity of the product, more predictable lot-to-lot uniformity, and free of concerns of immunogenicity [11-12]. Therefore the undertaken study aims at the development of AZT loaded PLGA microspheres for controlled release of the drug [13-14].

MATERIALS AND METHODS

Materials

AZT was obtained as a gift sample from Cadila Pharmaceutical Ltd, Ahmedabad (Gujrat). Light liquid paraffin, Heavy liquid paraffin, Glutaraldehyde have obtained from Himedia laboratories Mumbai (Maharashtra). PLGA was obtained from Sun Pharma, Vadodara (Gujrat) span 80 from SD Fine chemicals Mumbai (Maharashtra) and all other chemicals were of analytical grade.

Compatibility studies

Compatibility of drug and polymer was studied by obtaining IR spectra’s of drug and mixture of the drug with the polymer by FTIR spectrophotometer (Shimadzu 8400, Japan). The pure drug and mixture of drug-PLGA in the ratio of 1:1 were kept at room
temperatures (25°C was stirred at 1500 rpm and kept overnight at different
100 ml continuous phase containing 1% w/v span 80. The mixture
Preparation of AZT loaded PLGA microspheres
were prepared using a solvent evaporation method
with O/O and conventional W/O/O systems. In O/O method 100 mg
Microspheres were prepared using a solvent evaporation method
(25 mg) was added. This organic phase obtained was emulsified in
out by using a compound microscope. Dried microspheres were first re-
resulting microspheres were washed three times in n-hexane to
remove excessive surfactant on the surface and light mineral oil. The
resulting AZT-loaded microspheres were dried at-20°C for 24 h by
using freeze drier and then stored in a vacuum oven.
Characterization
Scanning electron microscopy (SEM) analysis
The surface morphology of the microspheres was investigated by Scanning Electron Microscopy (SEM). The microspheres were
mounted in metal stubs using a double-sided adhesive tape. After
being vacuum coated with a thin layer (100-150 Å) of gold, the
microspheres were examined by SEM at different magnification.
Percentage yield and particle size of AZT loaded PLGA microsphere
The particles were grossly separated. Particle size analysis was carried
out by using a compound microscope. Dried microspheres were first re-
dispersed in distilled water and placed on a glass slide and the number of
divisions of the calibrated eyepiece was counted by using a stage
micrometre. The average size of around 100 particles was determined.
The prepared microspheres were collected and weighed. The yield was
calculated for each batch by dividing the measured weight by the total
weight of non-volatile components
Loading efficiency
Microspheres equivalent to 100 mg of pure drug were crushed and
added to 50 ml of ethanol. The resulting mixture was shaken in a
mechanical shaker for 3 h to completely extract the drug. The
solution was filtered through Whatman filter paper and 1 ml of this
solution was appropriately diluted to 25 ml with ethanol and
analyzed spectrophotometrically at 266 nm using UV-Vis
spectrophotometer (Chemito-1600, Japan). Loading efficiencies were
calculated using the given formula (table 3).
Drug entrapment efficiency =
Drug actually present
Theoretical drug loaded
×100
Zeta potential study
The surface charge of microspheres was determined by the electrophoretic mobility of microspheres in a U type tube at 25°C ,
using a zeta sizer (Malvern, UK) (fig. 5).
In vitro drug release studies
A fabricated Franz diffusion cell was used. A dialysis membrane was
placed on the upper donor chamber of the diffusion cell, separating
this compartment from the receptor chamber. An accurately
weighed quantity of AZT-loaded microspheres (10 mg) was placed
on the membrane using a slab with an area of 1.77 cm² and thickness
of 1.2 mm. One ml of pH 7.4 150 ml PBS buffer containing 0.1% w/v
sodium azide and 0.05% w/v Tween 80 (PBS-T buffer) to prevent
microsphere contamination and agglomeration, respectively, was
added on the membrane. At fixed intervals, aliquots were withdrawn
from some cells and replenished with freshly prepared buffer. Tests
were performed in triplicate at 37±0.5 °C and 500 rpm. Samples
were analyzed using the UV spectrophotometer (Chemito-1600, Japan) (fig 7).
Stability study
The stability study of the selected formulation of the AZT loaded
microsphere was carried out by storing 1 gm of microparticles, in
an amber coloured screw capped bottle for a period of 1months at 40±2
⁰C temperature and 75±5% RH Using stability chamber (Thermo lab,
Mumbai). Sampling was carried out a 10days interval and examined
for percent entrapment. These samples were collected on 10, 20, 30
d and checked at regular intervals for Drug content.
Statistical analysis
All experiments were performed in triplicate manner. The data were
expressed as mean values±SEM using InStat software and tested
with analysis of variance followed by the multiple comparison test of
Tukey–Kramer with p<0.01 was considered significant.
RESULTS AND DISCUSSION
Compatibility studies
The FT-IR spectra of the free drug and the microspheres were
recorded. The drug-excipients compatibility studies reveal that there
are no physical changes observed in the drug and polymer mixtures.
The IR spectrum of the drug, drug-PLGA mixture and microspheres
formulation were compared to find any interaction between drug and
the polymer. It indicates that there is no
IR absorption peaks observed in the spectra of the drug were close
to those in the spectra of the microspheres indicates that there is no
interaction between the drug and the polymer. It indicates that
either the polymer nor the method of preparation has affected the
drug stability.
Formulation and characterization of PLGA microspheres
Non-aqueous solvent evaporation method was used to prepare AZT
loaded PLGA microsphere. The first trial was made to prepare
microspheres by using a solvent evaporation technique in the water
phase, using acetonitrile-water system but although many
formulations were investigated, no spherical particles could be
obtained.
Then acetonitrile/liquid paraffin system was used and various
formulations with different Drug:Polymer ratios were tried; stirring
speed was also changed to obtain spherical particle. Stirring speed
plays an important role in the microspheres size distribution and
drug loading. Microspheres were prepared by the method described
the optimized ratio of drug and the polymer (1:4), keeping
surfactant concentration (0.4%), utilizing three different speeds i.e.
1000, 1500, 2000rpm. It is an important parameter, which needs to
be optimized for optimum particle size and stability of the
microspheres.

Fig. 1: FTIR spectra of zidovudine
Span 80 was used as an emulsifier. Microspheres were prepared according to the method described above with optimized drug-polymer ratio i.e. 1:4 and stirring speed 1500 rpm with various concentrations i.e. 0.2%, 0.3%, 0.4% and 0.5% v/v of span 80. Among various D: P ratios 1:4 ratio and stirring speed was 1500 rpm, the best spherical particles with good surface characteristic were obtained. SEM of the microsphere prepared is shown in fig. 4.

The entrapment efficiency increased with an increase in polymer concentration. At 1:4 drug-polymer ratio (formulation A1) entrapment efficiency was found to be maximum 74.57%. Size range of microspheres in the 200-300 µm by all formulation (table 1). Increase the D: P ratio caused the mean particle size to shift towards a higher particle size. On increasing the stirring speed, the particle size of microspheres decreased. The yield of the preparation and AZT entrapment efficiencies was high for all formulations and maximum for optimized formulation. The values of the optimized formulation were shown in table 2.

These optimized parameters help to regulate the properties of the resulting biodegradable products which govern the release pattern of the drug [15-16].

### Table 1: Process variables for PLGA microspheres

| Formulation variables | Particle size | % entrapment efficiency |
|-----------------------|---------------|--------------------------|
| Drug: Polymer ratio   | µm            | %wt/wt                   |
| 1:01                  | 216±5.29      | 65.58±4.19               |
| 1:02                  | 238±3.84      | 70.42±5.27               |
| 1:03                  | 266±3.41      | 73.12±4.24               |
| 1:04                  | 285±3.78      | 74.57±4.19*              |
| 1:05                  | 294±3.19      | 72.68±4.67               |

| Emulsifier concentration | %entrapment efficiency |
|--------------------------|------------------------|
| 0.2                      | 68.42±3.21             |
| 0.3                      | 69.62±3.11             |
| 0.4                      | 74.42±3.87*            |
| 0.5                      | 68.2±5.17              |

| Stirring speed | %entrapment efficiency |
|----------------|------------------------|
| 1000           | 66.5±4.36              |
| 1500           | 75.1±4.41*             |
| 2000           | 68.3±5.67              |

SD; Standard Deviation for n=3.

### Table 2: Formula for microspheres after optimization

| Optimized parameters | Values |
|----------------------|--------|
| Drug: Polymer        | 1:4    |
| Emulsifier Conc (%w/v) | 0.4 |
| Stirring speed (rpm) | 1500  |
Table 3: Effect of various emulsifiers on morphology of PLGA microspheres

| Emulsifier                | AZT  | Solvent           | Continuous phase       | Morphology   |
|---------------------------|------|-------------------|------------------------|--------------|
| Span 80 (0.4 ml)          | 25 mg| Acetonitrile (5 ml)| Light mineral oil 40 ml | Very good    |
| Soyabean lecithin (0.4 ml)| 25 mg| Acetonitrile (5 ml)| Light mineral oil 40 ml | Good         |
| Span80 (0.4 ml)           | 25 mg| Acetonitrile (5 ml)| Soyabean oil:40 ml     | Not Good     |
| Soyabean lecithin (0.4 ml)| 25 mg| Acetonitrile (5 ml)| Soyabean oil:40 ml     | Not Good     |

Scanning electron microscopy (SEM) analysis

The surface topography of different formulation of microspheres was investigated by SEM. As seen in fig. 4, they were spherical in shape and exhibited porous surfaces. The SEM of Formulation B microspheres had rough surface due to a higher concentration of drug as compared to the other microspheres. SEM images of Formulation C and D showed rough and aggregated clump formation. Surface study of the microspheres after release study showed bigger pores suggesting that the drug was released through pores and the mechanism of drug release was diffusion controlled. The in vitro release of a drug from a biodegradable microparticulate system is affected by the properties of polymer and particles [17]. Controlling the release is to controlling the properties affecting release, including particle size, size distribution, drug content, polymer properties and surface properties [18].

![SEM Microphotograph of AZT loaded PLGA Microsphere prepared at different emulsifiers and continuous phases](image)

**Fig. 4: SEM Microphotograph of AZT loaded PLGA Microsphere prepared at different emulsifiers and continuous phases (1) Formulation A1 (2) Formulation B1 (3) Formulation C1 (4) Formulation D1**

Particle size and % yield of AZT loaded PLGA microsphere

The results of particle size and percentage yield mentioned in table 4. The % yield and the subsequent particle size of the respective formulations with the assigned product code were determined. Particle size was measured using an optical microscopy and mean particle size was calculated by measuring 200-300 particles with a calibrated ocular micrometre. The % yield was calculated using the following formula.

% Yield = (Total weight of floating microparticles/Total weight of drug and polymer) × 100

| S. No. | Product Code | % Yield | Particle Size (µm)   |
|--------|--------------|---------|----------------------|
| 1      | A1           | 80.20   | 282±3.8 µm           |
| 2      | C1           | 85.30   | 231±3.2 µm           |
| 3      | E1           | 75.75   | 264±4.2 µm           |

SD; Standard Deviation for n=3.

It has been well known that particle size and its distribution will significantly affect the in vitro release in microspheres system. For hydrophobic drugs, the removal of drugs out from boundary layer was crucial during drug release.

A high ratio of surface area and volume such as a decrease in the particle size always lead to a higher release. The particle size obtained was considered to be beneficial for faster drug release rate [19].

**Entrapment efficiency**

To 10 ml of ethanol, 50 µg of microparticles were crushed, suspended and was kept for 12 h for extraction of the drug. RG content was determined from the filtrate after suitable dilution spectrophotometrically at 300 nm. The percentage drug entrapment was calculated as follows: % Drug entrapment = (Calculated drug content/Theoretical drug content) × 100
Zeta potential study

Microparticles formulations were characterized also in terms of Zeta Potential because as well known it can influence particle stability. The electrostatic repulsion between particles with the same electric charge prevents the aggregation of the microsphere. In general, particle aggregation is less likely to occur for charged particles (high zeta potential) due to electric repulsion. On increasing the (D: P) 1:1, 1:2, 1:3, 1:4, 1:5 the zeta potential become-11.07, -18.20, -26.20, -39.80, -39.80 (table 5) and particle size 300.00, 282.00, 249.00, 202.20, 290.20. On increasing D: P the zeta potential turned more negative but when it came to 1:5 the zeta potential increased. Similar kind of change was observed in particle size; it increases on further increase in D: P ratio. The surface charge reversal can be attributed to the transfer of a proton from the bulk solution to the surface of the microsphere. A similar charge reversal with the change in pH has been observed for polystyrene nanoparticles with carboxyl functional groups on the surface [20-21].
Table 5: Zeta potential study

| S. No. | D P Ratio | Zeta Potential (mV) | Particle Size |
|--------|-----------|---------------------|---------------|
| 1      | 1:1       | -11.07              | 300.00        |
| 2      | 1:2       | -18.20              | 282.00        |
| 3      | 1:3       | -26.20              | 249.00        |
| 4      | 1:4       | -39.80              | 202.20        |
| 5      | 1:5       | -21.02              | 290.20        |

**In vitro release and kinetics study**

The cumulative percentage released in PBS buffer was 55.32±5.89 to 74.42±5.08 %. PLGA copolymer undergoes degradation by hydrolysis or biodegradation through cleavage of its backbone ester linkages into oligomers and finally monomers. This has been demonstrated in both in vivo and in vitro for various drug types and proteins with different polymer ratios [Ramchandani et al., 1998; Amann et al., 2010]. The degradation process for these polymers is mainly through uniform bulk degradation of the matrix where the water penetration into the matrix is higher than the rate of polymer degradation. The degradation of PLGA copolymer is the collective process of bulk diffusion, surface diffusion, bulk erosion and surface erosion. Since there are many variables such as molecular weight concentration, interaction with the carrier, diffusion and polymer-related variables such as size and density of particle, amount and type of matrix material surface erosion etc that influence the degradation process, the release rate pattern is often unpredictable. Formulation clearly showed initially burst release followed by sustained release, matrices having higher drug content possess a larger initial burst release than those having lower content because of their smaller polymer to drug ratio. The initial burst of drug release is related to drug type, drug concentration and polymer hydrophobicity. Drug on the surface, in contact with the medium is released as a function of solubility as well as penetration of water into the polymer matrix. Random scission of PLGA decreases the molecular weight of polymer significantly, but no appreciable weight loss and no soluble monomer product are formed in this phase. Then the drug is released progressively through the thicker drug depleted layer. The water inside the matrix hydrolyzes the polymer into soluble oligomeric and monomeric products. This creates a passage for the drug to be released by diffusion and erosion until complete polymer solubilisation. The best-selected in vitro release data of optimized formulation was fitted to various mathematical models such as zero order, first order, Higuchi and Peppas kinetic models. The highest regressions (0.981) was obtained for zero order kinetics followed by Higuchi (0.968) and first order (0.803) and Peppas (0.709) model. The drug release mechanism was found to be diffusion controlled and nearly zero order sustained release was observed.

![Graph showing cumulative in vitro release of PLGA microspheres](image)

Table 6: Correlation coefficient of the optimized batch

| S. No. | Zero order | First order | Higuchi | Krosmeyer Peppas |
|--------|------------|-------------|---------|------------------|
| 1      | 0.981      | 0.803       | 0.968   | 0.709            |

**Stability study**

International Conference on Harmonization (ICH) Guideline on drug stability Q1A (R2) requires that analysis of stability samples should be done by the use of validated stability-indicating analytical methods. It also recommends carrying out of stress testing on the drug substance to establish its inherent stability characteristics and to support the suitability of the proposed analytical procedure. The stress testing encompasses the influence of temperature, humidity, and light, oxidizing agents as well as susceptibility over a wide range of pH values.

We also try to study degradation of zidovudine under different ICH recommended stress conditions, and to establish a validated stability-indicating HPLC method. Zidovudine is chemically 3-azido-3-deoxythymidine. It is active against human immunodeficiency virus (HIV-I and-II) and human T-celllymphotropic virus (HTLV-I and-II). The drug is official in USP and BP. The drug is reported to exhibit acid and water catalyzed degradation and remained stable in alkali. Recently, its decomposition behaviour in hydrolytic and photolytic conditions was compared with stavudine. The stability of the drug in pharmaceutical dosage forms. However, there is no report yet on the development of stability-indicating assay method for the drug, employing ICH suggested approach. Otherwise, a number of reports are available for the determination of drug in the intracellular milieu and from biological fluids, such as plasma and urine.

A validated stability-indicating HPLC assay method was developed for zidovudine, using the stress-testing route suggested by ICH. The
The developed method is simple, accurate, precise, specific, and could separate drug from degradation products. It is suggested for use in analysis of samples generated during stability studies on zidovudine and its formulations. The stability study of the selected formulation of the AZT loaded microsphere was carried out by storing 1 gm of microparticles, in an amber colored screw capped bottle for a period of 1 months at 40±2 °C temperature and 75±5%RH Using stability chamber (Thermolab, Mumbai) Sampling was carried out a 10days interval and examined for percent entrapment (table 7).

Table 7: Stability data of the optimized batch

| Sampling time  | 0 D | 10 D | 20 D | 30 D |
|----------------|-----|------|------|------|
| Optimized Batch| 68.40±0.10 | 76.26±0.17 | 82.34±0.34 | 81.34±0.24 |

SD; Standard Deviation for n=3.

The drug decomposed under hydrolytic stress upon refluxing, and on exposure to light. It was stable to oxidation and thermal stress. The same major decomposition product could be seen in all the decomposed solutions, which was identified as thymine through comparison with the standard. Separation of drug from major and minor degradation products was successfully achieved on a C-18 column utilizing water–methanol in thereto of 75:25. The detection wavelength was 265 nm. The method was validated and the response was found to be linear in the drug concentration range of 25-500 µg/ml.

The mean values (±r, SD) of slope and correlation coefficient were 20, 659 and 0.9995, respectively. The R. SD values for intra-and inter-day precision were<0.6 and<1.2%, respectively. The method was established to have sufficient intermediate precision as similar separation was achieved on another instrument handled by a different operator. The recovery of the drug from a mixture of degraded samples ranged between 102.2 and 100.6%. PDA peak purity test confirmed the specificity of the method. The method was also successful in analysis of drug in marketed tablets subjected to stability testing under accelerated conditions of temperature, humidity, and to thermal and photolytic stress. The drug contents of the samples were analyzed after 10, 20 and 30 d of storage and there were no significant changes in the drug content. Hence, it can be concluded that the developed Zidovudine microsphere were stable and retained their pharmaceutical properties over a period of its shelf-life.

CONCLUSION
Microsphere coating or encapsulation with polymer using the double emulsion solvent diffusion method was investigated in this research. The results revealed that 216-306 μm microsphere was successfully coated or encapsulated in polymer. FT-IR analysis is another valuable qualitative analysis method of material characterization. PLGA microsphere has high percentage yield, entrapment efficiency, SEM Study with good reproducibility from batch to batch. This coating process is a promising environmentally friendly technique for microsphere coating/encapsulation with polymer with applications of pharmaceuticals and other products where chemical interactions must be avoided. The method used for the preparation of AZT loaded microparticles is a rapid and simple technique. The microspheres were of an appropriate size and suitable for oral administration. Thus the current investigation show promising results of PLGA microspheres as a matrix for drug delivery and merit for in vivo studies for scale up the technology.

ACKNOWLEDGEMENT
The authors are grateful to Dean SPS SOA University, Orissa for providing the valuable facility and guidance for my research work.

AUTHORS CONTRIBUTION
Kohli S makes substantial contributions to acquisition of data, analysis and interpretation of data and drafting the article. Jain S participates in concept, and data analysis and interpretation. Pal A participates in concept, guidance, critical review, and article revision.

CONFLICT OF INTERESTS
The authors have declared that there is no conflict of interest.
19. Zhang P, Chen L, Gu W. *In vitro* and *in vivo* evaluation of donepezil-sustained release microparticles for the treatment of Alzheimer's disease. Biomaterials 2007;28:1882-8.

20. Stolnik S, Garnett MC. The colloidal properties of surfactant free biodegradable nanospheres from (β-malic acid-co-benzyl malate)s and poly(lactic acid-co-glycolide). Colloids Surf 1995;97:235-45.

21. Makino K, Ohshima H, Kondo T. Transfer of protons from bulk solution to the surface of poly(L-lactide) microsphere. J Microencaps 1986;3:195-202.